TY - JOUR
T1 - Fructose induced KHK-C can increase ER stress independent of its effect on lipogenesis to drive liver disease in diet-induced and genetic models of NAFLD
AU - Park, Se Hyung
AU - Helsley, Robert N.
AU - Fadhul, Taghreed
AU - Willoughby, Jennifer L.S.
AU - Noetzli, Leila
AU - Tu, Ho Chou
AU - Solheim, Marie H.
AU - Fujisaka, Shiho
AU - Pan, Hui
AU - Dreyfuss, Jonathan M.
AU - Bons, Joanna
AU - Rose, Jacob
AU - King, Christina D.
AU - Schilling, Birgit
AU - Lusis, Aldons J.
AU - Pan, Calvin
AU - Gupta, Manoj
AU - Kulkarni, Rohit N.
AU - Fitzgerald, Kevin
AU - Kern, Philip A.
AU - Divanovic, Senad
AU - Kahn, C. Ronald
AU - Softic, Samir
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/8
Y1 - 2023/8
N2 - Non-alcoholic fatty liver disease (NAFLD) is a liver manifestation of metabolic syndrome, and is estimated to affect one billion individuals worldwide. An increased intake of a high-fat diet (HFD) and sugar-sweetened beverages are risk-factors for NAFLD development, but how their combined intake promotes progression to a more severe form of liver injury is unknown. Here we show that fructose metabolism via ketohexokinase (KHK) C isoform leads to unresolved endoplasmic reticulum (ER) stress when coupled with a HFD intake. Conversely, a liver-specific knockdown of KHK in mice consuming fructose on a HFD is adequate to improve the NAFLD activity score and exert a profound effect on the hepatic transcriptome. Overexpression of KHK-C in cultured hepatocytes is sufficient to induce ER stress in fructose free media. Upregulation of KHK-C is also observed in mice with genetically induced obesity or metabolic dysfunction, whereas KHK knockdown in these mice improves metabolic function. Additionally, in over 100 inbred strains of male or female mice hepatic KHK expression correlates positively with adiposity, insulin resistance, and liver triglycerides. Similarly, in 241 human subjects and their controls, hepatic Khk expression is upregulated in early, but not late stages of NAFLD. In summary, we describe a novel role of KHK-C in triggering ER stress, which offers a mechanistic understanding of how the combined intake of fructose and a HFD propagates the development of metabolic complications.
AB - Non-alcoholic fatty liver disease (NAFLD) is a liver manifestation of metabolic syndrome, and is estimated to affect one billion individuals worldwide. An increased intake of a high-fat diet (HFD) and sugar-sweetened beverages are risk-factors for NAFLD development, but how their combined intake promotes progression to a more severe form of liver injury is unknown. Here we show that fructose metabolism via ketohexokinase (KHK) C isoform leads to unresolved endoplasmic reticulum (ER) stress when coupled with a HFD intake. Conversely, a liver-specific knockdown of KHK in mice consuming fructose on a HFD is adequate to improve the NAFLD activity score and exert a profound effect on the hepatic transcriptome. Overexpression of KHK-C in cultured hepatocytes is sufficient to induce ER stress in fructose free media. Upregulation of KHK-C is also observed in mice with genetically induced obesity or metabolic dysfunction, whereas KHK knockdown in these mice improves metabolic function. Additionally, in over 100 inbred strains of male or female mice hepatic KHK expression correlates positively with adiposity, insulin resistance, and liver triglycerides. Similarly, in 241 human subjects and their controls, hepatic Khk expression is upregulated in early, but not late stages of NAFLD. In summary, we describe a novel role of KHK-C in triggering ER stress, which offers a mechanistic understanding of how the combined intake of fructose and a HFD propagates the development of metabolic complications.
KW - ER stress
KW - Fructose
KW - Ketohexokinase
KW - NAFLD
KW - Sugar
UR - http://www.scopus.com/inward/record.url?scp=85162871064&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85162871064&partnerID=8YFLogxK
U2 - 10.1016/j.metabol.2023.155591
DO - 10.1016/j.metabol.2023.155591
M3 - Article
C2 - 37230214
AN - SCOPUS:85162871064
SN - 0026-0495
VL - 145
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
M1 - 155591
ER -